FORT WORTH, Texas, Sept. 11 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today its strategic plans for the remainder of the year and for 2009. "The company has been focused on bringing the science and technology to the market for the first 3 quarters of the year to position CellerateRx(TM) as the number one collagen-based wound care product in the world. We have been working with several major medical groups, physicians and scientists across the US to validate our belief that CellerateRx is a 'one-of-a-kind' collagen product," stated CEO Scott Haire.
"With our patented technology and the way CellerateRx works when it is applied to an open wound, we don't believe that there is any other topical wound care product that can perform as well as CellerateRx," he went on to say. The company will present the product this week at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing (NCVH) conference in New Orleans, September 10-13.
"This year we wanted to establish ourselves as the leading collagen product in the $2 billion plus US wound care market by providing science and evidence-based studies behind CellerateRx.
We believe that these efforts will enable us to strategically grow our revenue base in 2009."
The company has leveraged its internal relationships and has focused on the US nursing home market to date. In addition to extended US sales channels, the company is currently working on leads in international markets with distributors that have major interest in the CellerateRx product. The international prevalence of diabetes and its related wounds have spurred sales interests in both the US and international markets.
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at http://www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the
company's expectations with regard to the future impact on the company's
results from new products in development are "forward-looking statements,"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Since this information may contain statements that involve risk and
uncertainties and are subject to change at any time, the company's actual
results may differ materially from expected results. This document may
contain forward-looking statements concerning the Company's operations,
current and future performance and financial condition. These items involve
risks and uncertainties such as product demand, market and customer
acceptance, the effect of economic conditions, competition, pricing, the
ability to consummate and integrate acquisitions, and other risks and
uncertainties detailed in the Company's SEC filings. The Company undertakes
no obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events.
For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
|SOURCE Wound Management Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved